Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer
Authors:
- 29 April 2022
- journal article
- research article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 23 (5) , e325-e329
Abstract
No abstract availableKeywords
Funding Information
- Merck & Co Inc
- Merck Sharp and Dohme United Kingdom
- National Institutes of Health
- National Cancer Institute (P30 CA008748)
This publication has 16 references indexed in Scilit:
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung CancerCancer Discovery, 2019
- Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 StudyJournal of Clinical Oncology, 2019
- Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung CancerJournal of Clinical Oncology, 2018
- Current standards for clinical management of small cell lung cancerTranslational Lung Cancer Research, 2018
- Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trialThe Lancet Oncology, 2017
- Small Cell Lung Cancer2016
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 BlockadeCancer Research, 2014
- Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancerCancer Medicine, 2014
- Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung CancerClinical Cancer Research, 2013
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1Cancer Discovery, 2012